---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-082793"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2022-03-23T23:59:59+00:00"
generated_at: "2026-06-26T19:38:22.762264+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Director Frederick W. Gluck to retire from CytomX board effective June 30, 2022

## Summary
- Frederick W. Gluck to retire from CytomX board effective June 30, 2022.
- Retirement not due to any dispute or disagreement with the company.
- No replacement named; board will be reduced by one member.

## SEC filing metadata
- accession: 0001193125-22-082793
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2022-03-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312522082793/0001193125-22-082793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312522082793/d340177d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-082793
- JSON: https://secwatch.observer/filing/0001193125-22-082793.json
- Plain text: https://secwatch.observer/filing/0001193125-22-082793.txt

## Key facts
- Executive change
  Frederick W. Gluck retired as director at CytomX Therapeutics, Inc..
  - Action: retired
  - Role: director
  source text: On March 23, 2022, CytomX Therapeutics, Inc. (the “Company”) announced the retirement of Frederick W. Gluck from the Company’s board of directors, effective as of June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312522082793/0001193125-22-082793-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.